Progress of Research into the Interleukin-1 Family in Cardiovascular Disease

References

• Liberale L, Montecucco F, Tardif JC, Libby P, Camici GG. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. Eur Heart J. 2020;41(31):2974–2982. doi:10.1093/eurheartj/ehz961
   PubMed Web of Science ®Google Scholar
• Sidney S, Go AS, Jaffe MG, Solomon MD, Ambrosy AP, Rana JS. Association between aging of the US population and heart disease mortality from 2011 to 2017. JAMA Cardiol. 2019;4(12):1280–1286. doi:10.1001/jamacardio.2019.4187
   PubMed Web of Science ®Google Scholar
• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi:10.1016/j.jacc.2020.11.010
   PubMed Web of Science ®Google Scholar
• Paneni F, Diaz Cañestro C, Libby P, Lüscher TF, Camici GG. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol. 2017;69(15):1952–1967. doi:10.1016/j.jacc.2017.01.064
   PubMed Web of Science ®Google Scholar
• Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79(8):837–847. doi:10.1016/j.jacc.2021.12.017
   PubMed Web of Science ®Google Scholar
• Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230–240. doi:10.1038/nrcardio.2017.154
   PubMed Web of Science ®Google Scholar
• Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–212. doi:10.1038/s41569-018-0119-4
   PubMed Web of Science ®Google Scholar
• Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation. 2016;133(16):1605–1620. doi:10.1161/circulationaha.114.008729
   PubMed Web of Science ®Google Scholar
• Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020;17(6):327–340. doi:10.1038/s41569-019-0326-7
   PubMed Web of Science ®Google Scholar
• Soehnlein O, Libby P. Targeting inflammation in atherosclerosis — from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589–610. doi:10.1038/s41573-021-00198-1
   PubMed Web of Science ®Google Scholar
• Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18(9):666–682. doi:10.1038/s41569-021-00552-1
   PubMed Web of Science ®Google Scholar
• Ye J, Que B, Huang Y, et al. Interleukin-12p35 knockout promotes macrophage differentiation, aggravates vascular dysfunction, and elevates blood pressure in angiotensin II-infused mice. Cardiovasc Res. 2019;115(6):1102–1113. doi:10.1093/cvr/cvy263
   PubMed Web of Science ®Google Scholar
• Zhang M, Gao J, Zhao X, et al. p38α in macrophages aggravates arterial endothelium injury by releasing IL-6 through phosphorylating megakaryocytic leukemia 1. Redox Biol. 2021;38:101775. doi:10.1016/j.redox.2020.101775
   PubMed Web of Science ®Google Scholar
• Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89–102. doi:10.1038/nri2691
   PubMed Web of Science ®Google Scholar
• Kanneganti T-D, Phimister EG. Inflammatory Bowel Disease and the NLRP3 inflammasome. N Engl J Med. 2017;377(7):694–696. doi:10.1056/NEJMcibr1706536
   PubMed Web of Science ®Google Scholar
• Dmitrieva-Posocco O, Dzutsev A, Posocco DF, et al. Cell-type-specific responses to interleukin-1 control microbial invasion and tumor-elicited inflammation in colorectal cancer. Immunity. 2019;50(1):166–180.e7. doi:10.1016/j.immuni.2018.11.015
   PubMed Web of Science ®Google Scholar
• Afsar B, Covic A, Ortiz A, Afsar RE, Kanbay M. The future of IL-1 targeting in kidney disease. Drugs. 2018;78(11):1073–1083. doi:10.1007/s40265-018-0942-2
   PubMed Web of Science ®Google Scholar
• Wong R, Lénárt N, Hill L, et al. Interleukin-1 mediates ischaemic brain injury via distinct actions on endothelial cells and cholinergic neurons. Brain Behav Immun. 2019;76:126–138. doi:10.1016/j.bbi.2018.11.012
   PubMed Web of Science ®Google Scholar
• Libby P, Kobold S. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases—expanding the concept of cardio-oncology. Cardiovasc Res. 2019;115(5):824–829. doi:10.1093/cvr/cvz058
   PubMed Web of Science ®Google Scholar
• Chan AH, Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J Exp Med. 2020;217(1):e20190314. doi:10.1084/jem.20190314
   PubMed Web of Science ®Google Scholar
• Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127(3):701–21.e1–70. doi:10.1016/j.jaci.2010.11.050
   Web of Science ®Google Scholar
• Garlanda C, Mantovani A. Interleukin-1 in tumor progression, therapy, and prevention. Cancer Cell. 2021;39(8):1023–1027. doi:10.1016/j.ccell.2021.04.011
   PubMed Web of Science ®Google Scholar
• Migliorini P, Italiani P, Pratesi F, Puxeddu I, Boraschi D. The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmun Rev. 2020;19(9):102617. doi:10.1016/j.autrev.2020.102617
   PubMed Web of Science ®Google Scholar
• Zhu AS, Mustafa T, Connell JP, Grande-Allen KJ. Tumor necrosis factor alpha and interleukin 1 beta suppress myofibroblast activation via nuclear factor kappa B signaling in 3D-cultured mitral valve interstitial cells. Acta Biomater. 2021;127:159–168. doi:10.1016/j.actbio.2021.03.075
   PubMed Web of Science ®Google Scholar
• Schunk SJ, Triem S, Schmit D, et al. Interleukin-1α is a central regulator of leukocyte-endothelial adhesion in myocardial infarction and in chronic kidney disease. Circulation. 2021;144(11):893–908. doi:10.1161/circulationaha.121.053547
   PubMed Web of Science ®Google Scholar
• Xiong S, Zhang L, Richner JM, Class J, Rehman J, Malik AB. Interleukin-1RA mitigates SARS-CoV-2-induced inflammatory lung vascular leakage and mortality in humanized K18-hACE-2 mice. Arterioscler Thromb Vasc Biol. 2021;41(11):2773–2785. doi:10.1161/atvbaha.121.316925
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kassem S, Cleynen A, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018;33(4):634–648.e5. doi:10.1016/j.ccell.2018.02.007
   PubMed Web of Science ®Google Scholar
• Vainchtein ID, Chin G, Cho FS, et al. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science. 2018;359(6381):1269–1273. doi:10.1126/science.aal3589
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981–983. doi:10.1056/NEJMc1811317
   PubMed Web of Science ®Google Scholar
• Huang Z, Xie L, Li H, et al. Insight into interleukin-37: the potential therapeutic target in allergic diseases. Cytokine Growth Factor Rev. 2019;49:32–41. doi:10.1016/j.cytogfr.2019.10.003
   PubMed Web of Science ®Google Scholar
• Sun X, Hou T, Cheung E, et al. Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma. Cell Mol Immunol. 2020;17(6):631–646. doi:10.1038/s41423-019-0300-7
   PubMed Web of Science ®Google Scholar
• Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260–1280. doi:10.1161/circresaha.120.315937
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Lazaridis A, Dogan S, et al. Theories and molecular basis of vascular aging: a review of the literature from vascagenet group on pathophysiological mechanisms of vascular aging. Int J Mol Sci. 2022;23(15):8672. doi:10.3390/ijms23158672
   PubMed Web of Science ®Google Scholar
• Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39(22):2063–2069. doi:10.1093/eurheartj/ehy128
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618–e651. doi:10.1161/cir.0000000000000617
   PubMed Web of Science ®Google Scholar
• Nagele P, Simplified A. Proposal to redefine acute myocardial infarction versus acute myocardial injury. Circulation. 2020;141(18):1431–1433. doi:10.1161/circulationaha.119.044996
   PubMed Web of Science ®Google Scholar
• Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2017;14(3):133–144. doi:10.1038/nrcardio.2016.185
   PubMed Web of Science ®Google Scholar
• Sun K, Li YY, Jin J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct Target Ther. 2021;6(1):79. doi:10.1038/s41392-020-00455-6
   PubMed Web of Science ®Google Scholar
• Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018;15(4):203–214. doi:10.1038/nrcardio.2017.161
   PubMed Web of Science ®Google Scholar
• Mozos I, Malainer C, Horbańczuk J, et al. Inflammatory markers for arterial stiffness in cardiovascular diseases. Front Immunol. 2017;8:1058. doi:10.3389/fimmu.2017.01058
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Thuren T, Libby P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur Heart J. 2020;41(23):2153–2163. doi:10.1093/eurheartj/ehz542
   PubMed Web of Science ®Google Scholar
• Giral H, Franke V, Moobed M, et al. Rapid inflammasome activation is attenuated in post-myocardial infarction monocytes. Front Immunol. 2022;13:857455. doi:10.3389/fimmu.2022.857455
   PubMed Web of Science ®Google Scholar
• Su Z, Lin R, Chen Y, et al. Knockdown of EMMPRIN improves adverse remodeling mediated by IL-18 in the post-infarcted heart. Am J Transl Res. 2015;7(10):1908–1916.
   PubMed Web of Science ®Google Scholar
• Maffia P, Grassia G, Di Meglio P, et al. Neutralization of interleukin-18 inhibits neointimal formation in a rat model of vascular injury. Circulation. 2006;114(5):430–437. doi:10.1161/circulationaha.105.602714
   PubMed Web of Science ®Google Scholar
• Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281(1):138–153. doi:10.1111/imr.12616
   PubMed Web of Science ®Google Scholar
• Xie SL, Chen YY, Zhang HF, et al. Interleukin 18 and extracellular matrix metalloproteinase inducer cross-regulation: implications in acute myocardial infarction. Transl Res. 2015;165(3):387–395. doi:10.1016/j.trsl.2014.09.001
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen Y, Chen Q, et al. Curcumin ameliorates cardiac fibrosis by regulating macrophage-fibroblast crosstalk via IL18-P-SMAD2/3 signaling pathway inhibition. Front Pharmacol. 2021;12:784041. doi:10.3389/fphar.2021.784041
   PubMed Web of Science ®Google Scholar
• Gu H, Xie M, Xu L, Zheng X, Yang Y, Lv X. The protective role of interleukin-18 binding protein in a murine model of cardiac ischemia/reperfusion injury. Transpl Int. 2015;28(12):1436–1444. doi:10.1111/tri.12683
   PubMed Web of Science ®Google Scholar
• Miller AM, Liew FY. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131(2):179–186. doi:10.1016/j.pharmthera.2011.02.005
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538–1549. doi:10.1172/jci30634
   PubMed Web of Science ®Google Scholar
• Xia N, Lu Y, Gu M, et al. A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction. Circulation. 2020;142(20):1956–1973. doi:10.1161/circulationaha.120.046789
   PubMed Web of Science ®Google Scholar
• Cheng X, Liao YH, Ge H, et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol. 2005;25(3):246–253. doi:10.1007/s10875-005-4088-0
   PubMed Web of Science ®Google Scholar
• Chen WY, Wu YH, Tsai TH, et al. Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis. Theranostics. 2021;11(6):2594–2611. doi:10.7150/thno.51648
   PubMed Web of Science ®Google Scholar
• Mia MM, Cibi DM, Ghani S, et al. Loss of Yap/Taz in cardiac fibroblasts attenuates adverse remodelling and improves cardiac function. Cardiovasc Res. 2022;118(7):1785–1804. doi:10.1093/cvr/cvab205
   PubMed Web of Science ®Google Scholar
• Melton E, Qiu H. Interleukin-36 cytokine/receptor signaling: a new target for tissue fibrosis. Int J Mol Sci. 2020;21(18):6458. doi:10.3390/ijms21186458
   PubMed Web of Science ®Google Scholar
• Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol. 2015;97(4):645–652. doi:10.1189/jlb.3RI1014-495R
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu J, Gao R, et al. Interleukin-36γ aggravates macrophage foam cell formation and atherosclerosis progression in ApoE knockout mice. Cytokine. 2021;146:155630. doi:10.1016/j.cyto.2021.155630
   PubMed Web of Science ®Google Scholar
• El-Awaisi J, Kavanagh DP, Rink MR, Weston CJ, Drury NE, Kalia N. Targeting IL-36 improves age-related coronary microcirculatory dysfunction and attenuates myocardial ischemia/reperfusion injury in mice. JCI Insight. 2022;7(5):e155236. doi:10.1172/jci.insight.155236
   PubMed Web of Science ®Google Scholar
• McCurdy S, Yap J, Irei J, Lozano J, Boisvert WA. IL-37-a putative therapeutic agent in cardiovascular diseases. Qjm. 2022;115(11):719–725. doi:10.1093/qjmed/hcab011
   PubMed Web of Science ®Google Scholar
• Mao X, Zhu R, Zhang F, et al. IL-37 plays a beneficial role in patients with acute coronary syndrome. Mediators Inflamm. 2019;2019:9515346. doi:10.1155/2019/9515346
   PubMed Web of Science ®Google Scholar
• Li J, Zhang WJ, Yao H, Li TM. Therapeutic effects of interleukin-37 and induced cardiosphere on treating myocardial ischemia-reperfusion injury. Int Immunopharmacol. 2020;88:106719. doi:10.1016/j.intimp.2020.106719
   PubMed Web of Science ®Google Scholar
• Wang YM, Zhang JJ, Wu BW, et al. IL-37 improves mice myocardial infarction via inhibiting YAP-NLRP3 signaling mediated macrophage programming. Eur J Pharmacol. 2022;934:175293. doi:10.1016/j.ejphar.2022.175293
   PubMed Web of Science ®Google Scholar
• Su Z, Tao X. Current understanding of IL-37 in human health and disease. Front Immunol. 2021;12:696605. doi:10.3389/fimmu.2021.696605
   PubMed Web of Science ®Google Scholar
• Zhu R, Zhang F, Pan C, Yu K, Zhong Y, Zeng Q. Role of IL-37- and IL-37-treated dendritic cells in acute coronary syndrome. Oxid Med Cell Longev. 2021;2021:6454177. doi:10.1155/2021/6454177
   PubMed Web of Science ®Google Scholar
• Tsilioni I, Pantazopoulos H, Conti P, Leeman SE, Theoharides TC. IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder. Proc Natl Acad Sci U S A. 2020;117(28):16475–16480. doi:10.1073/pnas.2004666117
   PubMed Web of Science ®Google Scholar
• Gao X, Chan PKS, Lui GCY, et al. Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections. Cell Death Dis. 2021;12(1):53. doi:10.1038/s41419-020-03283-2
   PubMed Web of Science ®Google Scholar
• van de Veerdonk FL, Stoeckman AK, Wu G, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A. 2012;109(8):3001–3005. doi:10.1073/pnas.1121534109
   PubMed Web of Science ®Google Scholar
• Mora J, Schlemmer A, Wittig I, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016;8(5):426–438. doi:10.1093/jmcb/mjw006
   PubMed Web of Science ®Google Scholar
• Li Z, Ding Y, Peng Y, et al. Effects of IL-38 on macrophages and myocardial ischemic injury. Front Immunol. 2022;13:894002. doi:10.3389/fimmu.2022.894002
   PubMed Web of Science ®Google Scholar
• Madhur MS, Elijovich F, Alexander MR, et al. Hypertension: do inflammation and immunity hold the key to solving this epidemic? Circ Res. 2021;128(7):908–933. doi:10.1161/circresaha.121.318052
   PubMed Web of Science ®Google Scholar
• Thomas JM, Ling YH, Huuskes B, et al. IL-18 (Interleukin-18) produced by renal tubular epithelial cells promotes renal inflammation and injury during deoxycorticosterone/salt-induced hypertension in mice. Hypertension. 2021;78(5):1296–1309. doi:10.1161/hypertensionaha.120.16437
   PubMed Web of Science ®Google Scholar
• Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. IL-1β and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol. 2014;171(24):5589–5602. doi:10.1111/bph.12876
   PubMed Web of Science ®Google Scholar
• Thomas JM, Huuskes BM, Sobey CG, Drummond GR, Vinh A. The IL-18/IL-18R1 signalling axis: diagnostic and therapeutic potential in hypertension and chronic kidney disease. Pharmacol Ther. 2022;239:108191. doi:10.1016/j.pharmthera.2022.108191
   PubMed Web of Science ®Google Scholar
• Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16(10):3046–3052. doi:10.1681/asn.2005030236
   PubMed Web of Science ®Google Scholar
• Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009;2009:137072. doi:10.1155/2009/137072
   PubMed Web of Science ®Google Scholar
• Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. 2018;113(1):5. doi:10.1007/s00395-017-0663-9
   PubMed Web of Science ®Google Scholar
• Ghali R, Altara R, Louch WE, et al. IL-33 (Interleukin 33)/sST2 axis in hypertension and heart failure. Hypertension. 2018;72(4):818–828. doi:10.1161/hypertensionaha.118.11157
   PubMed Web of Science ®Google Scholar
• Chen WY, Hong J, Gannon J, Kakkar R, Lee RT. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc Natl Acad Sci U S A. 2015;112(23):7249–7254. doi:10.1073/pnas.1424236112
   PubMed Web of Science ®Google Scholar
• Yin X, Cao H, Wei Y, Li HH. Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model. Hypertens Res. 2019;42(11):1664–1671. doi:10.1038/s41440-019-0291-x
   PubMed Web of Science ®Google Scholar
• Saxton SN, Whitley AS, Potter RJ, Withers SB, Grencis R, Heagerty AM. Interleukin-33 rescues perivascular adipose tissue anticontractile function in obesity. Am J Physiol Heart Circ Physiol. 2020;319(6):H1387–h1397. doi:10.1152/ajpheart.00491.2020
   PubMed Web of Science ®Google Scholar
• Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. Circ Res. 2020;126(6):789–806. doi:10.1161/circresaha.119.312321
   PubMed Web of Science ®Google Scholar
• Hall JE, Do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019;15(6):367–385. doi:10.1038/s41581-019-0145-4
   PubMed Web of Science ®Google Scholar
• Hu T, Wu Q, Yao Q, Jiang K, Yu J, Tang Q. Short-chain fatty acid metabolism and multiple effects on cardiovascular diseases. Ageing Res Rev. 2022;81:101706. doi:10.1016/j.arr.2022.101706
   PubMed Web of Science ®Google Scholar
• Giannoudaki E, Hernandez-Santana YE, Mulfaul K, et al. Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction. Nat Commun. 2019;10(1):4003. doi:10.1038/s41467-019-11944-w
   PubMed Web of Science ®Google Scholar
• Verhaar BJH, Collard D, Prodan A, et al. Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study. Eur Heart J. 2020;41(44):4259–4267. doi:10.1093/eurheartj/ehaa704
   PubMed Web of Science ®Google Scholar
• Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331–1340. doi:10.1161/hypertensionaha.115.05315
   PubMed Web of Science ®Google Scholar
• Adnan S, Nelson JW, Ajami NJ, et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genomics. 2017;49(2):96–104. doi:10.1152/physiolgenomics.00081.2016
   PubMed Web of Science ®Google Scholar
• Kaye DM, Shihata WA, Jama HA, et al. Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease. Circulation. 2020;141(17):1393–1403. doi:10.1161/circulationaha.119.043081
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Taniguchi Y, Matsumoto T, et al. Knockout of the interleukin-36 receptor protects against renal ischemia-reperfusion injury by reduction of proinflammatory cytokines. Kidney Int. 2018;93(3):599–614. doi:10.1016/j.kint.2017.09.017
   PubMed Web of Science ®Google Scholar
• Satiroglu O, Gürlek B, Durakoglugil ME, et al. The role of serum interleukin-37 levels, inflammation and blood pressure in patients with preeclampsia. Clin Exp Hypertens. 2020;42(7):669–674. doi:10.1080/10641963.2020.1772813
   PubMed Web of Science ®Google Scholar
• Ye J, Wang Y, Wang Z, et al. Circulating IL-37 levels are elevated in patients with hypertension. Exp Ther Med. 2021;21(6):558. doi:10.3892/etm.2021.9990
   PubMed Web of Science ®Google Scholar
• Ballak DB, Brunt VE, Sapinsley ZJ, et al. Short-term interleukin-37 treatment improves vascular endothelial function, endurance exercise capacity, and whole-body glucose metabolism in old mice. Aging Cell. 2020;19(1):e13074. doi:10.1111/acel.13074
   PubMed Web of Science ®Google Scholar
• Ballak DB, Li S, Cavalli G, et al. Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. J Biol Chem. 2018;293(37):14224–14236. doi:10.1074/jbc.RA118.003698
   PubMed Web of Science ®Google Scholar
• Lai M, Peng H, Wu X, Chen X, Wang B, Su X. IL-38 in modulating hyperlipidemia and its related cardiovascular diseases. Int Immunopharmacol. 2022;108:108876. doi:10.1016/j.intimp.2022.108876
   PubMed Web of Science ®Google Scholar
• Li Y, Chen S, Sun J, Yu Y, Li M. Interleukin-38 inhibits adipogenesis and inflammatory cytokine production in 3T3-L1 preadipocytes. Cell Biol Int. 2020;44(11):2357–2362. doi:10.1002/cbin.11428
   PubMed Web of Science ®Google Scholar
• Luo P, Zhao T, He H. IL-38-mediated NLRP3/caspase-1 inhibition is a disease-modifying treatment for TMJ inflammation. Ann N Y Acad Sci. 2022;1508(1):92–104. doi:10.1111/nyas.14704
   PubMed Web of Science ®Google Scholar
• Su Q, Yu XJ, Wang XM, et al. Na(+)/K(+)-ATPase Alpha 2 isoform elicits rac1-dependent oxidative stress and TLR4-induced inflammation in the hypothalamic paraventricular nucleus in high salt-induced hypertension. Antioxidants. 2022;11(2):288. doi:10.3390/antiox11020288
   Web of Science ®Google Scholar
• Byrne R, Constant O, Smyth Y, et al. Multiple source surveillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland. Eur Heart J. 2008;29(11):1418–1423. doi:10.1093/eurheartj/ehn155
   PubMed Web of Science ®Google Scholar
• Grune J, Yamazoe M, Nahrendorf M. Electroimmunology and cardiac arrhythmia. Nat Rev Cardiol. 2021;18(8):547–564. doi:10.1038/s41569-021-00520-9
   PubMed Web of Science ®Google Scholar
• Luan Y, Guo Y, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace. 2010;12(12):1713–1718. doi:10.1093/europace/euq321
   PubMed Web of Science ®Google Scholar
• Vm M, Al S, Aa A, et al. Circulating interleukin-18: association with IL-8, IL-10 and VEGF serum levels in patients with and without heart rhythm disorders. Int J Cardiol. 2016;215:105–109. doi:10.1016/j.ijcard.2016.04.002
   PubMed Web of Science ®Google Scholar
• Gupta A, Fei Y-D, Kim TY, et al. IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias. Blood. 2021;137(9):1208–1218. doi:10.1182/blood.2020005944
   PubMed Web of Science ®Google Scholar
• Li W, Li S, Li X, Jiang S, Han B. Interleukin-37 elevation in patients with atrial fibrillation. Clin Cardiol. 2017;40(2):66–72. doi:10.1002/clc.22630
   PubMed Web of Science ®Google Scholar
• Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011;8(3):162–172. doi:10.1038/nrcardio.2010.202
   PubMed Web of Science ®Google Scholar
• Bartoli-Leonard F, Zimmer J, Aikawa E. Innate and adaptive immunity: the understudied driving force of heart valve disease. Cardiovasc Res. 2021;117(13):2506–2524. doi:10.1093/cvr/cvab273
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhu J, Jiang L, Zhang B, Zhu D, Wu Y. Interleukin 18 promotes myofibroblast activation of valvular interstitial cells. Int J Cardiol. 2016;221:998–1003. doi:10.1016/j.ijcard.2016.07.036
   PubMed Web of Science ®Google Scholar
• Xu R, Zhu D, Guo J, Wang C. IL-18 promotes erythrophagocytosis and erythrocyte degradation by m1 macrophages in a calcific microenvironment. Can J Cardiol. 2021;37(9):1460–1471. doi:10.1016/j.cjca.2021.04.007
   PubMed Web of Science ®Google Scholar
• He Y-B, Guo J-H, Wang C, Zhu D, Lu L-M. IL-33 promotes the progression of nonrheumatic aortic valve stenosis via inducing differential phenotypic transition in valvular interstitial cells. J Cardiol. 2020;75(2):124–133. doi:10.1016/j.jjcc.2019.06.011
   PubMed Web of Science ®Google Scholar
• Garcia-Pena A, Ibarrola J, Navarro A, et al. Activation of the Interleukin-33/ST2 pathway exerts deleterious effects in myxomatous mitral valve disease. Int J Mol Sci. 2021;22(5):2310. doi:10.3390/ijms22052310
   PubMed Web of Science ®Google Scholar
• Kapelouzou A, Kontogiannis C, Tsilimigras DI, et al. Differential expression patterns of Toll Like Receptors and Interleukin-37 between calcific aortic and mitral valve cusps in humans. Cytokine. 2019;116:150–160. doi:10.1016/j.cyto.2019.01.009
   PubMed Web of Science ®Google Scholar
• Zeng Q, Song R, Fullerton DA, et al. Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proc Natl Acad Sci U S A. 2017;114(7):1631–1636. doi:10.1073/pnas.1619667114
   PubMed Web of Science ®Google Scholar
• Lu H, Rateri DL, Bruemmer D, Cassis LA, Daugherty A. Involvement of the renin–angiotensin system in abdominal and thoracic aortic aneurysms. Clin Sci. 2012;123(9):531–543. doi:10.1042/cs20120097
   PubMed Web of Science ®Google Scholar
• Anagnostakos J, Lal BK. Abdominal aortic aneurysms. Prog Cardiovasc Dis. 2021;65:34–43. doi:10.1016/j.pcad.2021.03.009
   PubMed Web of Science ®Google Scholar
• Suehiro C, Suzuki J, Hamaguchi M, et al. Deletion of interleukin-18 attenuates abdominal aortic aneurysm formation. Atherosclerosis. 2019;289:14–20. doi:10.1016/j.atherosclerosis.2019.08.003
   PubMed Web of Science ®Google Scholar
• Eckstein -H-H, Maegdefessel L. Linking obesity with abdominal aortic aneurysm development. Eur Heart J. 2020;41(26):2469–2471. doi:10.1093/eurheartj/ehz882
   PubMed Web of Science ®Google Scholar
• Zhang Z-B, Ruan -C-C, Lin J-R, et al. Perivascular adipose Tissue–Derived PDGF-D contributes to aortic aneurysm formation during obesity. Diabetes. 2018;67(8):1549–1560. doi:10.2337/db18-0098
   PubMed Web of Science ®Google Scholar
• Liu C-L, Ren J, Wang Y, et al. Adipocytes promote interleukin-18 binding to its receptors during abdominal aortic aneurysm formation in mice. Eur Heart J. 2020;41(26):2456–2468. doi:10.1093/eurheartj/ehz856
   PubMed Web of Science ®Google Scholar
• Li J, Xia N, Wen S, et al. IL (Interleukin)-33 suppresses abdominal aortic aneurysm by enhancing regulatory T-cell expansion and activity. Arterioscler Thromb Vasc Biol. 2019;39(3):446–458. doi:10.1161/atvbaha.118.312023
   PubMed Web of Science ®Google Scholar
• Koushki K, Shahbaz SK, Mashayekhi K, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60(2):175–199. doi:10.1007/s12016-020-08791-9
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang Z, Yuan Z, Lv S, Su Q. Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diab Vasc Dis Res. 2020;17(6):1479164120977441. doi:10.1177/1479164120977441
   Web of Science ®Google Scholar
• Ni X-Q, Hu Z-Y. Remifentanil improves myocardial ischemia-reperfusion injury in rats through inhibiting IL-18 signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(7):3915–3922. doi:10.26355/eurrev_202004_20858
   PubMed Web of Science ®Google Scholar
• Vanden Berghe T, Demon D, Bogaert P, et al. Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock. Am J Respir Crit Care Med. 2014;189(3):282–291. doi:10.1164/rccm.201308-1535OC
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zou J, Shi Z, et al. IL-22–induced cell extrusion and IL-18–induced cell death prevent and cure rotavirus infection. Sci Immunol. 2020;5(52):eabd2876. doi:10.1126/sciimmunol.abd2876
   PubMed Web of Science ®Google Scholar
• Abston ED, Barin JG, Cihakova D, et al. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Fail. 2012;5(3):366–375. doi:10.1161/circheartfailure.111.963769
   PubMed Web of Science ®Google Scholar
• Kim RY, Oliver BG, Wark PAB, Hansbro PM, Donovan C. COPD exacerbations: targeting IL-33 as a new therapy. Lancet Respir Med. 2021;9(11):1213–1214. doi:10.1016/s2213-2600(21)00182-x
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385(18):1656–1668. doi:10.1056/NEJMoa2024257
   PubMed Web of Science ®Google Scholar
• Stremska ME, Jose S, Sabapathy V, et al. IL233, A novel IL-2 and IL-33 hybrid cytokine, ameliorates renal injury. J Am Soc Nephrol. 2017;28(9):2681–2693. doi:10.1681/asn.2016121272
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Newstead MW, Zeng X, et al. Interleukin-36γ and IL-36 receptor signaling mediate impaired host immunity and lung injury in cytotoxic Pseudomonas aeruginosa pulmonary infection: role of prostaglandin E2. PLoS Pathog. 2017;13(11):e1006737. doi:10.1371/journal.ppat.1006737
   PubMed Web of Science ®Google Scholar
• Zhu J, Xu Y, Li Z, Liu S, Fu W, Wei Y. Interleukin-36β exacerbates DSS-induce acute colitis via inhibiting Foxp3+ regulatory T cell response and increasing Th2 cell response. Int Immunopharmacol. 2022;108:108762. doi:10.1016/j.intimp.2022.108762
   PubMed Web of Science ®Google Scholar
• Xu J, Chen J, Li W, et al. Additive therapeutic effects of mesenchymal stem cells and IL-37 for systemic lupus erythematosus. J Am Soc Nephrol. 2020;31(1):54–65. doi:10.1681/asn.2019050545
   PubMed Web of Science ®Google Scholar
• Wu Z, Mehrabi Nasab E, Arora P, Athari SS. Study effect of probiotics and prebiotics on treatment of OVA-LPS-induced of allergic asthma inflammation and pneumonia by regulating the TLR4/NF-kB signaling pathway. J Transl Med. 2022;20(1):130. doi:10.1186/s12967-022-03337-3
   PubMed Web of Science ®Google Scholar